Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease Start date pushed from Oct 2026 to Dec 2026 Universitaire Ziekenhuizen KU LeuvenNot specified NCT07906054
  2. Notable: Meal Sequence and Eating Speed on Blood Glucose After Eating Western Breakfast Among Healthy Young Adults Eligibility criteria changed University of Veterinary and Animal Sciences, Lahore - PakistanNot applicable NCT07932769
  3. Notable: Light Timing Study Results posted: Nov 17, 2026 Rush University Medical CenterNot applicable NCT04753190
  4. Notable: Pelvic Floor Ultrasound Before Induction of Labour and Labour Outcome Start date pushed from Oct 1, 2026 to Dec 1, 2026 University of Roma La SapienzaNot specified NCT07797387
  5. Notable: Prevention of Edema After Coronary Artery Bypass Graft by Customized Pressure-guided Elastic Bandages Primary completion date changed from estimate of Mar 31, 2026 to Nov 16, 2026 Siriraj HospitalNot applicable NCT06603961
  6. Notable: Real-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors · ASCVD for Secondary Prevention Eligibility criteria changed Xin LiNot specified NCT07938099
  7. Notable: Subclinical Renal Dysfunction in Rheumatoid Arthritis Start date pushed from Sep 1, 2026 to Nov 20, 2026 Assiut UniversityNot specified NCT07805109
  8. Notable: Designing a Spatial Navigation Intervention Protocol Informed by Region-specific Brain Activation for Mild Cognitive Impairment Eligibility criteria changed Albert Einstein College of MedicineNot applicable NCT07225400
  9. Notable: Digital ACT Psychological Support for Primary Caregivers · Severe Mental Illness Eligibility criteria changed Harbin Medical UniversityNot applicable NCT07931872
  10. Notable: Flavored Ready-to-Drink Alcohol Restriction in Young Adults: Behavioral and Biomarker Outcomes Start date pushed from Oct 2026 to Jan 2027 Medical University of South CarolinaNot applicable NCT07840625
  11. Notable: Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS) Start date pushed from Aug 27, 2026 to Sep 27, 2026 The University of Texas Medical Branch, GalvestonNot applicable NCT07758114
  12. Notable: Touch Methods on Pain and Physiological Parameters in Preterm Infants During Endotracheal Aspiration Primary completion date changed from estimate of Jul 1, 2025 to Jan 2, 2026 Acibadem UniversityNot applicable NCT05784857
  13. Notable: Confidence-Building and Diaphragmatic Breathing-Assisted Graded Exposure on Kinesiophobia and Anxiety During First Mobilization Among Women After Cesarean Section Eligibility criteria changed Ghadeer Fadhel AbbasNot applicable NCT07935577
  14. Notable: NIV-NAVA · Severe Bronchiolitis, a Pilot Multicenter Randomized Controlled Trial Start date pushed from Oct 2026 to Dec 1, 2026 St. Justine's HospitalNot applicable NCT07834723
  15. Minor: Hospital Initiation of Inclisiran Treatment · Acute Coronary Syndromes Enrollment closed, study ongoing Novartis PharmaceuticalsPhase 3 NCT07102628
  16. Minor: BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment · EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) Enrollment closed, study ongoing Sichuan Baili Pharmaceutical Co., Ltd.Phase 3 NCT06838273
  17. Minor: 5% Minoxidil Foam in Female Androgenetic Alopecia Trial completed Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Phase 3 NCT07080931
  18. Minor: Brivaracetam in Children and · Seizures Enrollment closed, study ongoing UCB Biopharma SRLPhase 3 NCT04715646
  19. Minor: IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Trial completed Innovent Biologics (Suzhou) Co. Ltd.Phase 3 NCT07473960
  20. Minor: Enlicitide · High Cholesterol (MK-0616-037) Trial completed Merck Sharp & Dohme LLCPhase 3 NCT07216482
  21. Minor: PYLARIFY® PET/CT or PET/MRI · Favorable Intermediate Risk (FIR) Prostate Cancer Trial completed Lantheus Medical ImagingPhase 4 NCT06074510
  22. Minor: Persistence of ACE1831, · IgG4-Related Disease Enrollment closed, study ongoing Acepodia Biotech, Inc.Phase 1/2 NCT07061938
  23. Minor: Gene Therapy Drug · Spinal Muscular Atrophy (SMA) Type 2 Patients Trial completed GeneCradle IncPhase 1/2 NCT05901987
  24. Minor: CRB-601-01 · Advanced Solid Tumor Trial completed Corbus Pharmaceuticals Inc.Phase 1/2 NCT06603844
  25. Minor: ARV-806 · Advanced Cancer That Has the KRAS G12D Mutation Trial completed Arvinas Inc.Phase 1/2 NCT07023731